新入荷
再入荷
70490-X/asset/f152d842-5737-42bf-9b6f-ab4fc5ec2377/main.assets/gr3_lrg.jpg "Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine")
00151-0/asset/3255eda7-ff4c-47cb-a17d-0a02d3dff490/main.assets/gr3_lrg.jpg "Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine")
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine
4.9
（5件）
タイムセール
終了まで
00
00
00
999円以上お買上げで送料無料（※）
999円以上お買上げで代引き手数料無料
999円以上お買上げで代引き手数料無料
通販と店舗では販売価格や税表示が異なる場合がございます。また店頭ではすでに品切れの場合もございます。予めご了承ください。
商品詳細情報
| 管理番号 |
新品 ：21351152219
中古 ：21351152219-1 |
メーカー | 6dce3e45004 | 発売日 | 2025-04-24 20:10 | 定価 | 15000円 | ||
|---|---|---|---|---|---|---|---|---|---|
| カテゴリ | |||||||||
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine,IMpower110 Clinical Trial Results | TECENTRIQ® (atezolizumab),Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma | New England Journal of Medicine,Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial - The Lancet Oncology,Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial - The Lancet Oncology
健康・医学の作品リスト
レディースの製品
